Amneal Reports Fourth Quarter and Full Year 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 2c
March 2, 2023 6:12 AM ESTAmneal Pharmaceuticals (: AMRX) reported Q4 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $610 million versus the consensus estimate of $579.84 million.
GUIDANCE:
Amneal Pharmaceuticals sees FY2023 revenue of $2.25-2.35 billion, versus the consensus of $2.31... More
